Company / Cash & Equivalents
Doximity Cash & Equivalents History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$209.6M
FY2025
5-year range
$66.4M / $209.6M
FY2021-FY2025
Trend
+116.6%
vs FY2024
Sector context
#84 of 152
Health Care
What the data says
At $210M, Doximity's cash & equivalents ranks #84 of 152 in the Health Care sector. Improved from $158M to $210M over the past 2 years.
Based on SEC 10-K filings.
$210M in FY2025 with a 3-year CAGR of +22.9%.
Improved from $158M to $210M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +22.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#84 of 152 in Health CareTop 55% of 152This company $209.6M Sector average $1.2B
▼
-82.2% below sector average
Key checks
Key Insights
- 3-year CAGR of +22.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 116.6% year-over-year.
- Ranks #84 out of 152 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- Strong profit margin: 39.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $209.6M | +116.6% |
| FY2024 | $96.8M | -38.8% |
| FY2023 | $158.0M | +40.1% |
| FY2022 | $112.8M | +69.9% |
| FY2021 | $66.4M | - |
| FY2020 | - | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026